Melanotan-2

Melanocortin Receptor Pharmacology Research

Receptor-binding and signal-transduction assays for the five-member melanocortin receptor family have used MT-II as a reference non-selective agonist for decades. The receptor pharmacology characterization is the most robust segment of the MT-II literature, with reported subnanomolar to low-nanomolar binding at MC1R and MC4R in transfected cell lines and a rank order approximately MC1R ≥ MC4R > MC3R > MC5R^[1][2].

The cyclic lactam structure that defines MT-II has served as a template for subsequent melanocortin-receptor probe development, including the receptor-selective antagonist series reported by Hruby and colleagues in 1995 using bulky aromatic substitutions at position 7^[8]. The receptor pharmacology platform produced two FDA-approved derivative drugs (bremelanotide for hypoactive sexual desire disorder, June 2019; afamelanotide for erythropoietic protoporphyria, October 2019) and one selective MC4R agonist (setmelanotide, approved 2020 for leptin-melanocortin pathway obesity syndromes), each of which narrowed the receptor profile or modified the dosing route relative to the non-selective MT-II prototype.

Melanogenesis Pathway Research

MC1R activation on melanocytes upregulates tyrosinase via cAMP / PKA / CREB signaling and shifts the eumelanin-to-pheomelanin ratio in cultured melanocytes and rodent skin preparations. The published preclinical melanogenesis literature for MT-II is well-developed and reproducible across frog (Rana pipiens), lizard (Anolis carolinensis), and mammalian skin bioassays, where the cyclic peptide was reported as approximately 90-100× more potent than native α-MSH^[2].

In the formal human research record, three small Arizona Phase I-II studies (combined n=33 male research subjects) reported observations on skin darkening following subcutaneous administration in the milligram range^[5][6][7]. No published human research has examined cosmetic outcomes in non-supervised settings, female subjects, or repeated long-term administration. The FDA-approved compound in the melanogenesis pathway is afamelanotide (Scenesse), the linear 13-mer parent, approved only for erythropoietic protoporphyria; no regulatory authority anywhere has approved any compound for cosmetic skin pigmentation.

MC4R-Pathway Sexual-Function Research

Central MC4R activation in the paraventricular nucleus and medial preoptic area has been implicated in the regulation of spontaneous erectile responses in male rodent and male research-subject preparations, mediated in part through downstream nitric oxide synthase activation. The Wessells 1998 study (n=10 men with psychogenic erectile dysfunction) and the Wessells 2000 study (n=20 men with organic erectile dysfunction) reported observations on penile rigidity by RigiScan recording following subcutaneous administration of MT-II in the microgram-per-kilogram range^[6][7].

This receptor pharmacology was the immediate scientific foundation for the bremelanotide HSDD development program at Palatin Technologies, which culminated in FDA approval of Vyleesi on June 21, 2019. Bremelanotide and MT-II are constitutional isomers differing only at the C-terminus (free acid vs primary amide); Vyleesi is approved only for hypoactive sexual desire disorder in premenopausal women under a single-occasion subcutaneous autoinjector regimen. MT-II itself has no regulatory approval for any sexual-function indication and is not the same molecule as Vyleesi.

Feeding and Energy-Homeostasis Research

Acute intracerebroventricular and peripheral MT-II administration has been reported to suppress food intake in fasted and free-feeding rodent preparations through joint MC3R and MC4R signaling. The effect has been characterized as partially dependent on dietary fat content and not strictly correlated with baseline obesity in rats on free-choice diet protocols.

The receptor-selective offshoot of this research program is setmelanotide (Imcivree, Rhythm Pharmaceuticals), an MC4R-selective agonist approved by FDA in 2020 for chronic body-mass control in patients with proopiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome. The clinical development that reached approval narrowed the receptor profile away from MT-II's non-selective signature; MT-II itself has not been clinically developed for any obesity indication and is not approved.

Published Safety Case-Report Literature

The published case-report literature on MT-II is unusually thick relative to the formal-trial literature, reflecting the population of non-supervised self-administering users that emerged after the 2000 Palatin development halt. Nelson, Bryant, and Aks reported a case of systemic toxicity with rhabdomyolysis in Clinical Toxicology (Philadelphia) 2012: a 39-year-old male injected a supra-therapeutic milligram dose of internet-sourced MT-II subcutaneously and presented within two hours with diffuse muscle pain, tachycardia, mydriasis, hypertension, elevated creatinine, and creatine kinase that peaked in the five-figure international-units range by twelve hours^[9]. Peters and colleagues in CEN Case Reports 2020 documented the first published case of renal infarction temporally associated with MT-II use: a 45-year-old previously healthy male presented with right-sided renal infarction affecting approximately half of the kidney, with persistent hypertension and reduced glomerular filtration rate at follow-up^[10]. Multiple priapism reports requiring corporal aspiration and intracavernosal phenylephrine have appeared in the urology literature, including Brun et al. (2019) and Habous et al. (2021) describing prolonged erections lasting nine to thirty hours after self-administration^[11][12].

The dermatology case-report literature includes at least four documented cases of melanoma diagnosis temporally associated with MT-II use, beginning with Paurobally et al. (2011) in British Journal of Dermatology and Hjuler and Lorentzen (2014) in Dermatology^[13][14]. The original Arizona research motivation for the entire melanotropin program was melanoma prevention via increased melanin density; the case-report record runs in the opposite direction. The published literature does not currently resolve whether the melanoma signal is causally attributable to MT-II's melanocortin pharmacology or reflects confounded UV-seeking behavior in the user population, but the case-report signal is well-documented^[15][16]. The Swedish Poisons Information Centre documented 215 MT-II-related adverse-event reports between 2008 and 2019, a tally that substantially exceeds the formal clinical-trial exposure^[10].

Replication & Safety Status

Three structurally related melanocortin-receptor agonists emerged from the Hruby and Hadley research program at the University of Arizona, and the catalog must keep them distinct. Melanotan-1 (afamelanotide) is a linear 13-mer, licensed by Clinuvel Pharmaceuticals, approved by FDA October 8, 2019 as Scenesse for the orphan indication of pain-free light exposure in adult erythropoietic protoporphyria patients. Bremelanotide is the cyclic 7-mer with a C-terminal free acid, licensed by Palatin Technologies, approved by FDA June 21, 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Melanotan-2 is the cyclic 7-mer with a C-terminal primary amide and has no regulatory approval anywhere in the world for any indication.

The MT-II safety case-report literature includes systemic toxicity with rhabdomyolysis (Nelson 2012)^[9], renal infarction (Peters 2020)^[10], multiple priapism cases requiring urological intervention (Brun 2019, Habous 2021)^[11][12], eruptive dysplastic nevi, at least four documented melanoma diagnoses temporally associated with use (Paurobally 2011, Hjuler 2014)^[13][14], and a 2009 Norwegian Adverse Drug Reactions Report case of sepsis with lung abscess and gluteal abscess with Staphylococcus aureus bacteremia following self-injection. The melanoma-induction paradox sits at the center of the safety record. The original Arizona research motivation was melanoma prevention via increased melanin density; the case-report record runs in the opposite direction^[15]. The 2015 Breindahl analytical study of three internet-sourced MT-II vials reported systematic under-filling (vials labelled at ten milligrams contained roughly four to nine milligrams of peptide) and 4.1-5.9% unidentified impurities, an analytical confirmation of underground product-quality concerns^[16].

The regulatory enforcement record on MT-II is dense and international. The FDA issued a warning letter to Melanocorp, Inc. and owner Edward Manookian on August 30, 2007, regarding marketing of MT-II as an injectable skin-pigmentation product; Manookian pled guilty to federal conspiracy charges in 2010 (after documented $929,000+ in post-warning MT-II sales plus false American-made advertising and customs mislabeling) and received a debarment order effective November 14, 2016 (Federal Register 2016-27244). The UK MHRA issued a public advisory in November 2008 that MT-II is an unlicensed medicine and supply is illegal under the Medicines Act 1968, triggered by 18 adverse-event reports detailing 74 separate reactions. The Australian TGA position pairs Schedule 4 prescription-only status under the Poisons Standard with non-listing on the Australian Register of Therapeutic Goods, and advertising to the public is prohibited under the Therapeutic Goods Act. Public warnings have also been issued by the Swedish Medical Products Agency, the Norwegian Medicines Agency (2007, 2009), the Danish Medicines Agency (2008), and the Irish Medicines Board (2009). The World Anti-Doping Agency lists MT-II under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a melanocortin agonist banned at all times on the WADA Prohibited List^[17].